Page 2 - Scientific Library

The synergistic combination of Poly(ADP-ribose) polymerases (PARP) and Topoisomerase I (Top1) inhibitors most beneficial on endonuclease-deficient cancer cells in cancer therapies ?

This is one

In a recent publication, Gole B. and Baumann C. demonstrate the role of the apoptotic nuclease EndoG in Mixed-Lineage Leukemia breakpoint cluster region (MLLbcr) destabilisation leading to MLL gene rearrangements

Several lines of evidence show that synthetic lethal interactions targeting DNA repair pathways may have clinical applications in cancer therapy. In a recent paper, Albarakati et al. demonstrate

In vivo monitoring of tumor growth and metastasis provides a powerful means for studying cancer properties and development of effective therapies. Mouse models created with tumor xenografts, resulting

Many labs have adopted the CRISPR genome editing technology to make knock-out and knock-in cell lines.

This technology produces first a targeted break in genomic DNA, which can then be exploited

In a recent post on  Venomous toxin ion channel modulators, we looked at toxin derived peptides to manipulate a wide variety of ion channels. These toxins can be used as tools to characterize

A crosstalk between cancer and immune cells is established during cancers. The immune system is able to fight against tumour cells (see my previous post "Immunosurveillance: Crosstalk between cancer and

Tumour immune evasion can be mediated by a complex set of interaction involving p53, miR-34 and PDL1. This is the conclusion of a work by Cortez et al. and recently published in JCNI .

The

The Blood-Brain Barrier (BBB) affects the development of drugs for all pathologies (brain exposure to drugs, side effects...). In the early phases of drug development, there is a strong need for stable

In the last few decades, in the field of Drug Discovery, Immunotherapy has gained more and more importance for the treatment of various diseases and in particular for certain types of

PD-1:PD:-L1 immune checkpoint pathway targeting immunotherapies have shown great potential for many cancer patients. Recently, The FDA has granted accelerated approval to the immunotherapy drug pembrolizumab

Gene reporter assays are widely used in research and Drug Discovery. The development of such cell lines is often time-consuming and costly, sometimes upwards of 5-20k € per cell line.